Moderna Inc said on Wednesday that an analysis of the early-stage data of its experimental COVID-19 vaccine showed it induced immune responses in older adults that were similar to those in younger participants. The company has so far enrolled over 13,000 participants in the late-stage trial. About 18% of the total participants are from minority groups that are the hardest hit by the pandemic. Moderna, which has no drugs on the market, has received nearly $1 billion from the U.S. government under Operation Warp Speed. It has also struck a $1.5 billion supply agreement with the United States.